Segment & Geographic Data Quant-Grade Normalized (live API) API & CSV Delivery

Alumis Inc's Business Segments

Alumis Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Segment Data As of Q1 FY2026

Reportable Segments

Per the company's own filing, this quarter

Largest Segment

Single reportable segment

100% of revenue

Total Revenue

$ 2

Consolidated, this quarter

Regions Reported

Geographic regions, this quarter

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/ALMS/segments                    

                        https://api.csimarket.com/api/v1/companies/ALMS/geographic                    

                        https://api.csimarket.com/api/v1/companies/ALMS/exposure                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Revenue Share by Reportable Segment - Q1 FY2026

Single reportable segment100%

Revenue by Reportable Segment - Q1 FY2026

Segment	Period	Revenue (Millions)	% of Total	Operating Income
Single reportable segment	Q1 FY2026	$ 2	100%	$ -98

Revenue by Product & Service Category - Q1 FY2026

Collaboration revenue100%

Revenue by Product & Service Category - Q1 FY2026

Category	Period	Revenue (Millions)	% of Total
Collaboration revenue	Q1 FY2026	$ 2	100%

Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.

Description of Alumis Inc

Alumis Inc. is a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases. Its lead programs include two Tyrosine Kinase 2 (TYK2) inhibitors: envudeucitinib (envu), a second-generation inhibitor in Phase 2 and Phase 3 trials for moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor in Phase 1 trials targeting neuroinflammatory and neurodegenerative diseases. In May 2025, Alumis acquired lonigutamab, a monoclonal antibody targeting IGF-1R for potential treatment of Thyroid Eye Disease, through the ACELYRIN merger. The company employs a proprietary precision data analytics platform to select validated drug targets and accelerate development. Alumis's strategy includes expanding clinical development of envu to additional indications, advancing A-005 for CNS diseases, discovering earlier-stage candidates such as interferon regulatory factor 5 (IRF5), and pursuing strategic collaborations to enhance the global impact of its product candidates and portfolio.